USP5 Promotes Head and Neck Squamous Cell Carcinoma Progression Via MTOR Signaling Pathway

Overview

Journal Cancer Med

Specialty Oncology

Date 2025 Mar 11

PMID 40066708

Authors

Ni Xiong

Yue Wang

Junhong Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Head and neck squamous cell carcinoma (HNSCC) is a highly aggressive malignancy characterized by limited prognostic markers and treatment options, contributing to high mortality rates. While Ubiquitin-specific peptidase 5 (USP5) has been implicated in various cancers, its role in HNSCC remains poorly understood.

Aims: This study aims to investigate the role of USP5 in the progression of HNSCC and explore its potential as both a prognostic biomarker and a therapeutic target.

Materials & Methods: This work utilized single-cell transcriptomic analysis with the Scissor algorithm to identify distinct epithelial subpopulations, particularly focusing on the Stress subpopulation that exhibited significant upregulation of USP5. Validation was conducted using tissue microarray (TMA) analysis and immunohistochemistry (IHC) to compare USP5 expression levels in HNSCC tissues versus adjacent normal tissues. Furthermore, RNA interference (RNAi) experiments were performed to knock down USP5 expression, assessing its effects on tumor cell behavior, including proliferation, migration, and invasion, as well as the regulation of mTORC1 and NF-κB signaling pathways.

Results: This study revealed that the Stress subpopulation, characterized by USP5 upregulation, was associated with enhanced tumor cell proliferation, migration, and invasion. TMA and IHC analyses confirmed that USP5 expression was significantly higher in HNSCC tissues compared to normal tissues, correlating with poor patient prognosis. Additionally, RNAi-mediated knockdown of USP5 led to reduced tumor cell activities and downregulation of the mTORC1 and NF-κB signaling pathways.

Discussion: The findings suggest that USP5 plays a critical role in driving HNSCC progression. Its overexpression in aggressive tumor subpopulations and association with poor clinical outcomes highlight its potential utility as both a prognostic biomarker and a therapeutic target. The observed effects on cell behavior and oncogenic signaling pathways provide mechanistic insights into how USP5 for HNSCC therapy.

Conclusions: This study establishes USP5 as a key driver of HNSCC progression, underscoring its potential role in prognosis and therapy. Targeting USP5 may offer novel treatment strategies for HNSCC, addressing the urgent need for effective therapeutic interventions in this aggressive malignancy.

References

Schinke H, Shi E, Lin Z, Quadt T, Kranz G, Zhou J . A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer. Mol Cancer. 2022; 21(1):178. PMC: 9454230. DOI: 10.1186/s12943-022-01646-1. View

Xiao W, Wang J, Wang X, Cai S, Guo Y, Ye L . Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression. Autophagy. 2022; 18(11):2615-2635. PMC: 9629121. DOI: 10.1080/15548627.2022.2044651. View

Huang C, Chen L, Savage S, Eguez R, Dou Y, Li Y . Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021; 39(3):361-379.e16. PMC: 7946781. DOI: 10.1016/j.ccell.2020.12.007. View

Murugan A . mTOR: Role in cancer, metastasis and drug resistance. Semin Cancer Biol. 2019; 59:92-111. DOI: 10.1016/j.semcancer.2019.07.003. View

Cai B, Zhao J, Zhang Y, Liu Y, Ma C, Yi F . USP5 attenuates NLRP3 inflammasome activation by promoting autophagic degradation of NLRP3. Autophagy. 2021; 18(5):990-1004. PMC: 9196652. DOI: 10.1080/15548627.2021.1965426. View

Glaviano A, Foo A, Lam H, Yap K, Jacot W, Jones R . PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023; 22(1):138. PMC: 10436543. DOI: 10.1186/s12943-023-01827-6. View

Bugter J, Fenderico N, Maurice M . Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2020; 21(1):5-21. DOI: 10.1038/s41568-020-00307-z. View

Zhang C, Li K, Zhu H, Cheng M, Chen S, Ling R . ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4 macrophage infiltration. Nat Commun. 2024; 15(1):7077. PMC: 11329676. DOI: 10.1038/s41467-024-51096-0. View

Li D, Sun A, Zhang L, Ding Z, Yi F, Yang X . Elevated ITGA5 facilitates hyperactivated mTORC1-mediated progression of laryngeal squamous cell carcinoma via upregulation of EFNB2. Theranostics. 2022; 12(17):7431-7449. PMC: 9691358. DOI: 10.7150/thno.76232. View

10.

Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X . Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022; 7(1):3. PMC: 8724284. DOI: 10.1038/s41392-021-00762-6. View

11.

Chaudhary S, Pothuraju R, Rachagani S, Siddiqui J, Atri P, Mallya K . Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring. Cancer Lett. 2021; 510:79-92. PMC: 8153085. DOI: 10.1016/j.canlet.2021.04.004. View

12.

Zhang M, Hoyle R, Ma Z, Sun B, Cai W, Cai H . FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program. Mol Ther. 2021; 29(8):2583-2600. PMC: 8353207. DOI: 10.1016/j.ymthe.2021.03.024. View

13.

Buckbinder L, St Jean Jr D, Tieu T, Ladd B, Hilbert B, Wang W . STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts. Cancer Discov. 2023; 13(11):2432-2447. PMC: 10618743. DOI: 10.1158/2159-8290.CD-23-0396. View

14.

Liu Y, Wang W, Zou L, Li L, Feng L, Pan M . Ubiquitin specific peptidase 5 mediates Histidine-rich protein Hpn induced cell apoptosis in hepatocellular carcinoma through P14-P53 signaling. Proteomics. 2017; 17(12). DOI: 10.1002/pmic.201600350. View

15.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

16.

Xia P, Zhang H, Lu H, Xu K, Jiang X, Jiang Y . METTL5 stabilizes c-Myc by facilitating USP5 translation to reprogram glucose metabolism and promote hepatocellular carcinoma progression. Cancer Commun (Lond). 2023; 43(3):338-364. PMC: 10009668. DOI: 10.1002/cac2.12403. View

17.

Cao L, Liu H, Huang C, Guo C, Zhao L, Gao C . USP5 knockdown alleviates lung cancer progression via activating PARP1-mediated mTOR signaling pathway. Biol Direct. 2023; 18(1):16. PMC: 10103446. DOI: 10.1186/s13062-023-00371-z. View

18.

Li K, Chen J, Zhang C, Cheng M, Chen S, Song W . The CTBP2-PCIF1 complex regulates m6Am modification of mRNA in head and neck squamous cell carcinoma. J Clin Invest. 2023; 133(20). PMC: 10575729. DOI: 10.1172/JCI170173. View

19.

Johnson D, Burtness B, Leemans C, Lui V, Bauman J, Grandis J . Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020; 6(1):92. PMC: 7944998. DOI: 10.1038/s41572-020-00224-3. View

20.

Sun H, Zhu A, Gao Y, Terajima H, Fei Q, Liu S . Stabilization of ERK-Phosphorylated METTL3 by USP5 Increases mA Methylation. Mol Cell. 2020; 80(4):633-647.e7. PMC: 7720844. DOI: 10.1016/j.molcel.2020.10.026. View